These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 23012806)

  • 1. [Role of RAAS inhibitors for the treatment of heart failure].
    Murohara T
    Nihon Rinsho; 2012 Sep; 70(9):1577-81. PubMed ID: 23012806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The renin-angiotensin-aldosterone system and heart failure.
    Sayer G; Bhat G
    Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes.
    Albaghdadi M; Gheorghiade M; Pitt B
    Eur Heart J; 2011 Nov; 32(21):2626-33. PubMed ID: 21672933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex differences in heart failure medications targeting the renin-angiotensin-aldosterone system.
    Nicolaou PA
    Eur J Pharmacol; 2021 Apr; 897():173961. PubMed ID: 33617824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of RAAS inhibition in diabetic nephropathy].
    Tsuruya K; Toyonaga J
    Nihon Rinsho; 2012 Jul; 70 Suppl 5():411-8. PubMed ID: 23156430
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
    Lambers Heerspink HJ
    Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome?
    Sexton DJ
    Circ Heart Fail; 2014 May; 7(3):536. PubMed ID: 24847129
    [No Abstract]   [Full Text] [Related]  

  • 9. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
    Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P
    JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart failure therapy: what should clinicians believe?
    Fang JC
    JAMA; 2012 Nov; 308(20):2144-6. PubMed ID: 23188032
    [No Abstract]   [Full Text] [Related]  

  • 12. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock.
    van Diepen S; Reynolds HR; Stebbins A; Lopes RD; Džavík V; Ruzyllo W; Geppert A; Widimsky P; Ohman EM; Parrillo JE; Dauerman HL; Baran DA; Hochman JS; Alexander JH
    Crit Care Med; 2014 Feb; 42(2):281-8. PubMed ID: 23982033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Salt-induced inappropriate augmentation of intrarenal RAAS and its treatment in patients with chronic kidney disease].
    Konishi Y
    Nihon Rinsho; 2012 Sep; 70(9):1588-92. PubMed ID: 23012808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
    Nochioka K; Sakata Y; Shimokawa H
    Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.
    Ruiz-Hurtado G; Ruilope LM
    Eur Heart J Cardiovasc Pharmacother; 2015 Apr; 1(2):126-31. PubMed ID: 27533982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What constitutes optimal neurohumoral antagonism in chronic heart failure?
    Tajik AA; Dickstein K
    Heart; 2016 Dec; 102(23):1922-1932. PubMed ID: 27742799
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?
    Nehme A; Zibara K
    Hypertens Res; 2017 Nov; 40(11):903-909. PubMed ID: 28680167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of RAAS--when is it too much?
    Navarro P; Moskowitz R; Le Jemtel TH
    Curr Heart Fail Rep; 2004 Jul; 1(2):57-64. PubMed ID: 16036026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future.
    Orsborne C; Chaggar PS; Shaw SM; Williams SG
    Postgrad Med J; 2017 Jan; 93(1095):29-37. PubMed ID: 27671772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention.
    Vijayaraghavan K; Deedwania P
    Cardiol Clin; 2011 Feb; 29(1):137-56. PubMed ID: 21257105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.